英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
cxlvii查看　cxlvii　在百度字典中的解释百度英翻中〔查看〕
cxlvii查看　cxlvii　在Google字典中的解释Google英翻中〔查看〕
cxlvii查看　cxlvii　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Atezolizumab for Bladder Cancer - NCI - National Cancer Institute
    The Food and Drug Administration (FDA) on May 18 approved atezolizumab (Tecentriq®) for the treatment of some patients with urothelial carcinoma, the most common type of bladder cancer The drug, which strengthens the body’s immune response against cancer, is the first new treatment approved for bladder cancer in two decades
  • Atezolizumab with or without chemotherapy in metastatic urothelial . . .
    Addition of atezolizumab to platinum-based chemotherapy as first-line treatment prolonged progression-free survival in patients with metastatic urothelial carcinoma The safety profile of the combination was consistent with that observed with the individual agents 2016, with MeSH search terms “metastatic” AND “bladder cancer
  • Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
    2 Overview on Approved Immune Checkpoint Inhibitors for Metastatic Bladder Cancer 2 1 Atezolizumab Atezolizumab is a humanized anti-PD-L1 IgG1 antibody with minimal binding to Fc receptors Its use has been approved by FDA on the basis of the results of the IMvigor 210 study Cohort 2 of this trial included patients who had disease
  • Atezolizumab: Immunotherapeutic for Bladder Cancer | AACR Foundation
    Bladder cancer is the fifth most commonly diagnosed cancer in the United States An estimated 76,960 U S adults will be diagnosed with bladder cancer and 16,390 people will die from the disease in 2016 Urothelial carcinoma accounts for 90 percent of all cases, according to Roche, the company that manufactures atezolizumab
  • FDA approves new, targeted treatment for bladder cancer
    The U S Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma This is the first product in its class
  • Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer
    These data suggest that patients with advanced bladder cancer treated with atezolizumab have significantly better response rates and survival than historical controls treated with other second-line regimens The toxicity profile of atezolizumab is also favorable Trials are currently assessing whether atezolizumab is effective in earlier
  • FDA Approves Atezolizumab for Bladder Cancer - Medscape
    Atezolizumab is the first and only anti-PDL1 cancer immunotherapy It is also the first new treatment option in metastatic bladder cancer in more than 30 years
  • Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
    In summary, evidence from phase I and II trials suggests durable activity of atezolizumab in advanced bladder cancer that has progressed during or after platinum-based chemotherapy A combined analysis of 10 phase II trials of second-line therapies for metastatic bladder cancer showed an average 1-year OS of 20% Given that the 1-year OS of
  • Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive . . .
    Background: Radical cystectomy (RC) is the standard of care for patients with BCG-unresponsive high risk non-muscle invasive bladder cancer (NMIBC), but many patients are unfit for surgery or elect bladder preservation This trial was designed to evaluate the activity of atezolizumab in BCG-unresponsive high risk NMIBC Methods: This single arm phase II registration trial testing systemic
  • Second line immune checkpoint inhibition in urothelial cancer
    With approval of the first CPI atezolizumab in 2016 in the second line setting, the treatment of mUC has changed dramatically plus cisplatin in patients with bladder cancer J Clin Oncol 2005;23:4602-8 10 1200 JCO 2005 07 757 [Google Scholar] 4 Bellmunt J, Theodore C, Demkov T, et al Phase III trial of vinflunine plus best supportive





中文字典-英文字典  2005-2009